Will GLAXO BE Progressing SRA737 ORAL Following Their Acquisition Of Sierra Oncology ? . The Highly Potent Chk1 Inhibitor Has Been Gathering Dust With Sierra For Over 2 Years . Unusual Given It Showed Complete Tumour Regression In SMALL CELL LUNG CÁNCER .